Pharmacological rhythm versus rate control in patients with atrial fibrillation and heart failure: the CASTLE-AF trial
| Autor: | Nassir F. Marrouche, Christian Mahnkopf, Prashanthan Sanders, Karl Wegscheider, Heribert Schunkert, Christian Sohns, Anna Suling, Johannes Brachmann, Vinay Krupadev, Yan Zhao, Luca Boersma, Susanne Sehner, Lilas Dagher |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Population Adrenergic beta-Antagonists Digitalis 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Heart Rate Physiology (medical) Internal medicine Atrial Fibrillation Clinical endpoint medicine Humans Sinus rhythm 030212 general & internal medicine education Aged Heart Failure education.field_of_study biology business.industry Hazard ratio Atrial fibrillation Middle Aged medicine.disease biology.organism_classification Confidence interval Hospitalization Heart failure Cardiology Female Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents |
| Zdroj: | Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 61(3) |
| ISSN: | 1572-8595 |
| Popis: | The value of antiarrhythmics to maintain normal sinus rhythm in patients with atrial fibrillation (AF) and heart failure (HF) is still being debated. We aimed to determine whether rhythm control using antiarrhythmic drugs (AADs) is more effective than rate control in improving outcomes in this population. In this sub-analysis of the CASTLE-AF study, we included patients that were treated pharmacologically either to maintain sinus rhythm or to achieve rate control. The primary endpoint was defined as a composite of death from any cause or worsening of HF that led to an unplanned overnight hospitalization. Among 210 patients (mean age of 64.1 ± 10.8 years, 83.3% male) treated pharmacologically, 60 patients were in the rhythm control group and 150 were in the rate control group. Patients in the rhythm control group were less likely to be assigned a beta-blocker (53 (88.3%) vs 141 (97.9%), P = 0.004) and digitalis (8 (13.3%) vs 53 (36.8%), P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink